Document is current
Any future updates will be listed below
-
Authors
Shashaty, Michael G. S. https://orcid.org/0000-0002-8766-3418
Reilly, John P.
Faust, Hilary E.
Forker, Caitlin M.
Ittner, Caroline A. G.
Zhang, Peggy X.
Hotz, Meghan J.
Fitzgerald, David
Yang, Wei
Anderson, Brian J.
Holena, Daniel N.
Lanken, Paul N.
Christie, Jason D.
Meyer, Nuala J.
Mangalmurti, Nilam S.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (P50HL060290, P01HL079063, K24HL115354, K08HL131995, K08HL098362, K23HL125723, K23HL140482)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK111638)
Congressionally Directed Medical Research Programs (W81XWH-15-1-0363)
- License Information
-
More Information
Article History
Received: 20 December 2018
Accepted: 19 May 2019
First Online: 28 June 2019
Ethics approval and consent to participate
: The MESSI and PETROS prospective cohorts were approved by the University of Pennsylvania Institutional Review Board. Informed consent was obtained from patients enrolled in MESSI. PETROS was approved by the IRB with a waiver of informed consent.
: Not applicable.
: Dr. Meyer reports institutional funding from GlaxoSmithKline and served on the advisory board for SOBI, Inc. Dr. Christie reports institutional funding from GlaxoSmithKline. Dr. Mangalmurti reports receipt of RIP1KD mice and RIP1K inhibitors from GlaxoSmithKline for murine studies to determine the role of RIP1K dependent necroptosis in transfusion mediated lung injury. The remaining authors declare that they have no competing interests.
